Home > Inhibitors & Agonists > JAK/STAT Signaling
Cat. No. Product name CAS No.
DC10428 (1S,3R,5R)-PIM447 dihydrochloride

(1S,3R,5R)-PIM447 (dihydrochloride) an PIM inhibitor extracted from patent US 20100056576 A1, compound example 72, has IC50 values of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3.

DC12010 ML116

A novel selective STAT3 inhibitor with IC50 of 4.2 uM, does not inhibit STAT1, STAT5, or NFkB signaling pathways (IC50>50 uM).

744270-00-6
DC11882 HJC0416

A orally bioavailable small-molecule STAT3 inhibitor.

1617518-22-5
DC12009 CPA-7

A platinum-containing compound that disrupts STAT3 signaling, inhibits cell growth and induces apoptosis in STAT3-activated cancer cells.

16961-77-6
DC21158 JAK3-IN-2 Featured

A potent and highly selective JAK3 inhibitor with IC50 of 0.15 nM.

1443235-95-7
DC11736 PF-956980

A potent, highly specific JAK3 inhibitor with IC50 of 4 nM.

1262832-74-5
DC2096 AG490 Featured

AG-490 (Tyrphostin B42) is an inhibitor of EGFR, ErbB2 and JAK2 with IC50 of 0.1 μM, 13.5 μM, and ~10 μM, respectively.

133550-30-8
DC8256 AS 602801(Bentamapimod) Featured

AS 602801(Bentamapimod) is a novel, orally active inhibitor of JNK.

848344-36-5
DC11420 AS-1517499 Featured

AS1517499 is a potent STAT6 inhibitor with IC50 of 21 nM.

919486-40-1
DC7367 AZ-960

AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3.

905586-69-8
DC5012 AZD1208 Featured

AZD1208 is orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity.

1204144-28-4
DC5032 AZD1480

AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1/2.

935666-88-9
DC5064 Baricitinib (INCB28050, LY3009104) Featured

Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2,showed potent activity against COVID-19(SARS-COV-2).

1187594-09-7
DC8258 Baricitinib phosphate Featured

Baricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2,showed potent activity against COVID-19(SARS-COV-2).

1187595-84-1
DC4175 BMS-911543

BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, approximately 350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively.

1271022-90-2
DC8040 STAT3 Inhibitor XVIII, BP-1-102 Featured

BP-1-102 is a potent, orally bioavailable and selective STAT3 inhibitor.

1334493-07-0
DC9704 BTZ043 Featured

BTZ043 is a inhibitor of decaprenyl-phosphoribose-epimerase (DprE1), It can display nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro.

1161233-85-7
DCAPI1392 BTZ043 racemate

BTZ043 racemate is a decaprenylphosphoryl-β-D-ribose 2-epimerase (DprE1) inhibitor acting as a new antimycobacterial agent that kill Mycobacterium tuberculosis.

957217-65-1
DC10864 C188-9 Featured

C188-9 is a potent inhibitor of STAT3 that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors.

432001-19-9
DC7099 CEP33779 Featured

CEP33779(< 3 μM) inhibits phosphorylation of downstream target signal transducer and activator of transcription 5(pSTAT5) of JAK2 in a concentration dependent manner in HEL92 cells.

1257704-57-6
DC7814 Cerdulatinib(PRT-062070; PRT2070)

Cerdulatinib(PRT-062070; PRT2070) is an novel oral dual Syk/JAK inhibitor.

1198300-79-6
DC10341 CHZ868 Featured

CHZ868 is a type II JAK2 inhibitor with an IC50 of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

1895895-38-1
Page 1 / Total 4 FirstPrevNextLastGoto